Hoffmann-la Roche Inc.

Roche Glycart Ag

F. Hoffmann-la Roche Ag

Thomas Friess

Christian Klein

Birgit Bossenmaier

Edgar Voss

Walter-Gunar Friebe

Irene Kolm

Guy Georges

Hans-Willi Krell

Ekkehard Moessner

Lothar Kling

Matthias Rueth

Valeria Lifke

Pablo Umana

Georg Fertig

Ulrike Reiff

Nikolaos Dimoudis

Max Hasmann

Tilman Schlothauer

Sabine Imhof-Jung

Stefan Dengl

Werner Scheuer

Jens Fischer

Marlene Thomas

Christian Schantz

Frank Herting

Claudio Sustmann

Thomas Von Hirschheydt

Frieder Bauss

Sebastian Fenn

Bernhard Goller

Barbara Weiser

Adrian Zwick

Meher Majety

Christian Gerdes

Martin Weisser

Charles Dumontet

Rolf Juchem

Christian Geletneky

Ben-Fillippo Krippendorff

Katharina Wartha

Oliver Krieter

The invention provides anti-TPBG antibodies and methods of using the same.

Anti-TPBG antibodies and methods of use

The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Anti-HER3 antibodies and uses thereof

The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.

Combination therapy of anti-HER3 antibodies

The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.

Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

The present invention provides the compounds of formula (I) their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Ether derivatives

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Phenylpyridine derivatives

The present invention provides the compounds of formula I their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Oxidized thioether derivatives

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Indole derivatives

The present invention 1 includes compounds of formula (I), and their pharmaceutically acceptable salts. These compounds are useful in the control or prevention of cancer.

Oxazole derivatives

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Benzylether derivatives

Objects of the present invention are the compounds of formula (I) formula (I),their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

Thioether derivatives

Growing community of inventors

Diessen-Dettenhofen, Germany

Thomas Friess